Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia

Annals of Hematology
Fei GaoYanmin Zhao

Abstract

Post-transplantation thrombocytopenia (PT) is a common and severe complication which usually leads to poor prognosis. Eltrombopag (EPAG), a novel oral thrombopoietin (TPO) receptor agonist, has shown promising effects in thrombocytopenia due to immune thrombocytopenic purpura (ITP) and refractory severe aplastic anemia (rSAA), while the effectiveness of EPAG for PT patients still needs to be evaluated. A total of 32 PT patients receiving EPAG were retrospectively analyzed between September 2017 and July 2019, including 15 patients with poor graft function (PGF) and 17 patients with secondary failure of platelet recovery (SFPR). To date, 21 (65.6%) patients achieved overall recovery (OR) and 14 (43.8%) patients achieved complete recovery (CR). Among responders, 18 (85.7%) patients discontinued or tapered the drug and 16 (76.2%) patients successfully maintained their best response. During the EPAG treatment, responders received much lower median platelet transfusion units than non-responders (11 vs. 95, P < 0.001). After a median follow-up time of 364 days (range, 24-842), the overall survival in these patients was 78.1% (100% for responders and 36.4% for non-responders, P < 0.001). In the univariate and multivariate analysis, PG...Continue Reading

References

Jul 1, 1988·European Journal of Haematology·H Wadenvik, J Kutti
Feb 24, 2001·European Radiology·F RobertsonO Ekberg
Jul 6, 2012·The New England Journal of Medicine·Matthew J OlnesCynthia E Dunbar
Dec 12, 2012·Bone Marrow Transplantation·G AkpekV T Ho
Jan 20, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Takashi TanakaTakahiro Fukuda
Jun 12, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu AkahoshiYoshinobu Kanda
Dec 13, 2016·Expert Review of Hematology·Massimo FranchiniGiuseppe Lippi
Mar 23, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Armin GhobadiJohn F DiPersio
Apr 11, 2018·Blood·Zhen ZhaoThomas Winkler
Jun 23, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yang SongYuan Kong
Jan 27, 2019·Bone Marrow Transplantation·Serena MarottaAntonio M Risitano
Feb 3, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Cai YuanShahram Mori
Apr 16, 2019·Experimental Hematology·Kacey L GuentherAndre Larochelle
Jun 4, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leyre BentoUNKNOWN Grupo Español de Trasplante Hematopoyético (GETH)
Jun 10, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yanmin ZhaoHe Huang
Jul 19, 2019·International Journal of Molecular Sciences·Fanny Vardon-BounesVincent Minville
Feb 18, 2020·Pediatric Blood & Cancer·Riccardo MasettiFranco Locatelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.